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Alzheimer’s disease (AD) is the most frequent progressive 
neurodegenerative disorder in elderly associated with irreversible cognitive 
impairment and dementia. The vast majority of AD patients are sporadic 
(SAD) in which the disease develops after age of 65. Despite of century of 
research, we lack understanding of the SAD etiology and pathogenesis. Several 
hypotheses try to explain the main causes of brain degeneration in SAD, one of 
them assuming that genomic instability and the reentry of certain neurons into 
the incomplete cell cycle may be the pathogenic basis of the disease. Although 
the brain is the most affected organ in AD, numerous studies showed structural 
and functional alterations in peripheral tissues, suggesting that AD is a 
generalized systemic disorder. Diverse changes in peripheral cells from AD 
patients are described in literature including cell cycle aberration and 
chromosome instability, alterations in cell viability, proliferation and 
apoptosis, oxidative metabolism, amyloid precursor protein and amyloid β 
protein metabolism, and other cellular processes. The aim of this paper was to 
summarize and review the results of our investigations and the growing 
literature data concerning the multiple chromosomal alterations in peripheral 
cells of AD patients and to consider their possible role in the disease 
pathogenesis as well as the importance of such investigations.    
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INTRODUCTION 
Alzheimer’s disease (AD) is the most frequent progressive neurodegenerative disorder 
in elderly associated with irreversible cognitive impairment and dementia. There are two forms 
of the disease; 5-10% of all AD cases have an early onset form that starts before the age of 65, 
while the vast majority of patients are sporadic (SAD) in which the disease develops after age of 
65.  Up to 50% of early onset cases are familial AD (FAD), diagnosed when a patient has first-
degree relative with history of AD (BIALOPIOTROWICZ et al., 2011). FAD, as genetically 
determined AD, seems to be completely explained by pathogenic mutations in three genes, either 
for amyloid precursor protein (APP) (APP gene on chromosome 21), or enzymes involved in its 
metabolism: Presenilin 1 gene on chromosome 14, and Presenilin 2 gene on chromosome 1 
(SHERRINGTON et al., 1995). Presenilins sustain the activity of γ-secretase, a membranous 
complex that cleaves transmembrane APP to generate amyloid β (Aβ) peptides (Aβ40, Aβ42) 
known to aggregate and form oligomers that may exert toxic effects on neurons (TAGAMI et al., 
2008). In contrast to FAD, SAD is a disorder with more heterogeneous and complex causes, 
which are mostly unknown (BUIZZA et al., 2012). Both incidence and prevalence of SAD 
increase with advanced age, suggesting that age-related physiological changes play a critical role 
in the majority of subjects affected with AD (CORRADA et al., 2008). Although late onset AD is 
considered sporadic, the fact that affected individuals are more likely to have AD-affected 
relatives than those without AD means that SAD is not fully sporadic (HENDRIE, 1998). Some 
risk factor genes has been uncovered, but only the mutation of apolipoprotein E-4 gene is present 
in considerable number (about 50%) of SAD patients (CORDER et al., 1993). Therefore, SAD is 
multifactorial, genetically complex and heterogeneous disorder modulated by different non-
genetic factors (FERRER, 2012).   
 AD is characterized histopathologically by the degeneration of specific populations of 
the neurons, extracellular deposits known as senile plaques (SPs) and intracellular deposits 
known as neurofibrillary tangles (NFTs) within the brain of affected individuals. SPs consist of 
Aβ42 and/or Aβ40, which originate from the aberrant proteolysis of APP (HARDY, 2006), and it 
is assumed that Aβ triggers AD-like pathology (KHANDELWAL et al., 2011). The NFTs contain 
structures known as paired helical filaments comprised of hyperphosphorylated tau protein 
(THOMAS and FENECH, 2007). In addition to Aβ, tau protein is another causal factor for 
neurodegeneration in AD and other neurodegenerative diseases (GRUNDKE-IQBAL et al., 1989).                  
 Over a hundred of years after Alois Alzheimer first characterized the neurological 
disease that was later named after him, the etiology and pathophysiology of AD are still mostly 
unknown. Several hypotheses try to explain causes and progression of the disease, especially the 
SAD form. Since this neurological disorder is complex and multifactorial, a single hypothesis is 
probably insufficient to cover all aspects of the disease. 
 According to the “amyloid hypothesis”, which is one of the first hypotheses introduced, 
Aβ has the central role in AD pathogenesis (HARDY, 2006). The similarity of histopathological 
hallmarks in FAD and SAD led to assumption that a common pathophysiological mechanism 
underlies both forms of the disease. An elevated level of neurotoxic Aβ in certain brain 
structures is the primary cause for AD that drives other disease features including tau 
phosphorylation. However, the amyloid hypothesis emerged out of molecular defects found to be 
causative primarily in FAD, though not necessary in SAD (SMALL and DUFF, 2008).     
 The “cell cycle hypothesis” assumes that the pathogenic basis of AD is genomic 
instability and the aberrant reentry of terminally differentiated postmitotic neurons into the cell 
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division cycle (ARENDT, 2003; HERNANDEZ-ORTEGA et al., 2007; BAJIC et al., 2008; BONDA et 
al., 2010; BAJIC et al., 2011; SPREMO-POTPAREVIC et al., 2011). In the hippocampal and cerebral 
cortex regions of postmortem SAD brains, increased levels of numerous proteins characteristic 
for G1/S and G2 cell cycle phase activation was accompanied by partial or complete DNA 
replication without signs of mitosis (YANG and HERRUP, 2007; SPREMO-POTPAREVIĆ et al., 2008; 
BONDA et al. 2009). Cells in unaffected brain regions of SAD patients or non-demented control 
brains show no such anomalies. Data indicate that the G1/S checkpoint fails in SAD neurons and 
therefore these cells replicate their DNA and progress to the G2 phase (MCSHEA et al., 2007). 
However, the G2/M checkpoints remain functional and block completion of the cell cycle, i.e. the 
mitosis, of affected neurons. These changes appear to occur at early stages of SAD, while at the 
advanced stages the affected neurons exhibit pathological changes characteristic of 
neurodegeneration and higher susceptibility to death triggered by stress factors (YANG and 
HERRUP, 2007). The period between the neuronal reentry into the cell cycle and apoptotic death 
may last for years or even decades (MOSCH et al., 2007). 
 Although AD is mainly considered a neurodegenerative disorder, there are many indices 
for additional involvement of cerebrovascular pathology leading to the “neurovascular 
hypothesis” in AD pathogenesis (ZLOKOVIC, 2005). It is suggested that chronic endothelial 
dysfunction may be responsible for breakdown of blood brain barrier, impaired cerebrovascular 
flow, cerebral amyloid angiopathy, atherosclerosis, and other important secondary-related 
inflammatory phenomena found in AD cases (BELL and ZLOKOVIC, 2009).  
 Mitochondrial structural and functional perturbations in AD have been recognized for 
some time (SELFRIDGE et al., 2012) and one of the latest hypotheses is about the potential role of 
mitochondrial dysfunction in AD pathogenesis, which is not brain-localized, but rather seems to 
be systemic. Thus, SWERDLOW and KHAN (2004) proposed the “mitochondrial cascade 
hypothesis”, according to which inherited mutation in mitochondrial DNA determined the basal 
function of mitochondria as well as their ability to respond to and recover from stress that is 
mediated by molecules such as reactive oxygen species (ROS). At the point at which 
mitochondrial dysfunction is reached, the histopathology of AD develops. Current data suggest 
that mitochondrial dysfunction, by influencing cell bioenergetic states and redox system, actually 
lies upstream of brain amyloidosis (SELFRIDGE et al., 2012) 
 Until now, AD cannot be diagnosed by a valid clinical method or marker before the 
disease has progressed to the stage in which dementia is developed and any effective cure is 
missing. Apart of neuropsychological assessment, several biomarkers are currently available for 
the clinical diagnosis of dementia of Alzheimer’s type: reduced levels of Aβ and increased ratio 
of phospho-tau/tau in cerebrospinal fluid, increasing atrophy of certain cerebral regions such as 
hippocampus and amygdala revealed by structural magnetic resonance imaging and increasing 
positron emission tomography signals of accumulated proteins in the brain, such as Aβ and tau 
(BLENNOW et al., 2006). Unfortunately, these procedures are either invasive or expensive, which 
preclude their frequent usage. Extensive investigations for accessible and reliable biomarkers for 
an early AD diagnosis are in progress.  
Although the brain is the most affected organ in AD, numerous studies showed 
structural and functional alterations in peripheral tissues, suggesting that AD is a generalized 
systemic disorder (GASPARINI et al., 1998; PALOTAS et al 2002; MIGLIORE et al., 2005; HUMPEL, 
2011; MIGLIORE, et al., 2011; STIELER, et al., 2012). Due to the inaccessibility of brain tissue in 
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vivo, peripheral tissues of AD patients that are suitable and most frequently explored are 
peripheral blood cells, skin fibroblasts and the cells from buccal mucosa. 
 Diverse changes that occur in peripheral cells from AD subjects include cell cycle 
aberration and genome or chromosome instability, alterations in cell viability, proliferation and 
apoptosis, oxidative metabolism, APP and Aβ metabolism, cellular signal transduction systems, 
calcium homeostasis, and some other cellular processes. The question is rising whether the 
changes at periphery reflect the situation in AD brain or do they contribute to pathogenesis or 
even to etiology of AD. It is rather unlikely that all these multiple AD-related changes are 
independent, and their investigation could lead to a common link to brain cells and peripheral 
somatic cells (GIBSON and HUANG, 2005). On the other hand, because of their easy accessibility, 
peripheral cells may be of great importance for identification of biological markers of AD and 
can be tremendously useful to improve diagnostic accuracy and/or monitor the efficiency of 
putative therapies (UBERTI et al., 2008).  
In this review we will summarize the results of our, over a decade long, investigations 
and the growing literature data concerning the multiple genome/chromosome alterations and 
abnormalities in peripheral cells of AD patients, compare them with the changes in neurons of 
AD brain, and consider their putative consequences as well as the possible importance of these 
investigations.   
 
GENOME/CHROMOSOME INSTABILITY IN ALZHEIMER’S DISEASE 
 Mounting evidence suggests that the cell cycle disregulation and genomic instability 
may be the earliest neuropathological event detected in AD thus far (ZHOU and JIA, 2010). These 
failures are systemic affecting not only neurons but also peripheral somatic cells (STIELER, et al., 
2012). AD is associated with elevated frequencies of genomic instability markers including cell 
cycle abnormalities and aneuploidy, and chromosome instability such as premature centromere 
division, micronuclei and telomere length change (ŻEKANOWSKI and WOJDA, 2009).  
 The cell cycle disregulation is the most prominent failure in AD in both neurons and 
some peripheral somatic cells (BIALOPIOTROWICZ et al., 2011; MOH et al., 2011; STIELER et al., 
2012). Post-mitotic neurons are in a state of terminal differentiation and are unable to divide but 
they may still retain certain elements that are active during cell cycle maintaining the capability 
to reactivate various aspects of the replication mechanism when stressed (HERRUP et al., 2004). 
The most important endogenous genotoxic agent associated with DNA damage in the earliest 
stage of AD is oxidative stress (NUNOMURA et al., 2001). Oxidative stress appears closest to a 
causal event in AD, acknowledging that previous events may be promoting the oxidative stress 
itself (MONDRAGON-RODRIGUEZ et al., 2010). The presence of Aβ early in the disease also 
contributes to the oxidative damage of DNA (MAO and REDDY, 2011). According to hypothesis 
of YUROV and colleagues (2011) incomplete DNA replication, being highly probable in 
postmitotic cells, causes replication forks to progress slowly or to stall resulting in S phase arrest 
or replication stress, which leads to DNA damage or improper repair and, thereby, to 
accumulation of genomic instabilities. The surveillance system of cell cycle checkpoints 
functions as protective barriers against cytotoxic agents by providing attacked cells additional 
time, by so called cell cycle arrest, to repair DNA damage before DNA replication or mitosis 
(SHACKELFORD et al.,  2000). When damage is severe and irreparable, checkpoint signaling may 
cause cells to undergo apoptosis, which is the ultimate result of cell cycle aberration in neurons, 
or enter an irreversible G0 state.   
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 Examination of cell cycle of peripheral AD cells reveals similar defects with neurons in 
AD. In the B lymphocytes of SAD, but not FAD, patients a prolongation of the G1 phase of cell 
cycle compared to controls was found (BIALOPIOTROWICZ et al., 2011). The level of p21 protein, 
one of the major regulators of G1/S progression in the cell cycle, was much higher in the SAD 
cells compared with both control and FAD cells. Cyclin-dependent  kinase  inhibitor  p21  is a  
p53-inducible  protein,  which  mediates  p53-dependent  cell  cycle arrest (DOTTO, 2000). 
Cytogenetic anomalies in AD neurons and lymphocytes (MIGLIORE et al., 2005; COPPEDÈ and 
MIGLIORE, 2009) may result in upregulation of p21 in both cell types. Importantly, the results of 
BIALOPIOTROWICZ et al. (2011) directly show differences in the cell cycle regulation between 
FAD and SAD, as far as lymphocytes concerned. ZHOU and JIA (2010) also observed the 
abnormality in G1/S checkpoint of the activated lymphocytes from AD patients. They found that 
AD lymphocytes were less sensitive to G1/S transcription blocker rapamycin than control cells. 
Because of the G1/S checkpoint dysfunction, the cell cycle of AD lymphocytes was not arrested 
in G1 phase and progress to late stages in spite of rapamycin treatment. In addition, AD 
lymphocytes specifically expressed an anomalous conformationally mutant-like p53 that made 
these cells distinct from lymphocytes of control subjects. Tumor suppressor protein p53, which 
promotes transcription of p21, has therefore a critical role in regulation G1/S cell cycle arrest 
(KUERBITZ et al., 1992). Exposure to multiple signals, including radiation, genotoxic chemicals, 
hypoxia and oxidative stress, induces p53 to accumulate in the nucleus, to bind to specific DNA 
sequences and to transactivate several genes most of them involved in cell-cycle control, DNA 
repair, and apoptosis (ALMONG and ROTTER, 1997). On the other hand, conformational changes 
of p53 in AD might be one possible reason for p53 inactivation and multiple disturbances in 
affected cells. Based on their results, ZHOU and JIA (2010) propose two potential biomarkers in 
blood lymphocytes from AD patients: the G1/S checkpoint dysfunction and the presence of 
conformationally mutant-like p53 protein. Of note, recent data demonstrated that combination of 
p53 phosphorylated at ser 15 and p21 in peripheral blood lymphocytes have high diagnostic 
power and could differentiate AD from controls and other types of dementia, indicating these 
proteins as potential biomarkers for improving diagnostic accuracy of AD (TAN et al., 2012).  
Aneuploidy, a state of non-diploid chromosome number, is a form of genomic 
instability and may be one of the hallmarks of aging and neurological disorders (BAJIĆ et al., 
2012; ŽIVKOVIĆ et al., 2013). Aneuploidy is defined as the loss or gain of chromosomes to 
produce a numerical deviation from multiples of the haploid chromosomal complement (KING 
and STANSFIELD, 1990). A correlation between aneuploidy and aging has been reported (MOSCH 
et al., 2007; THOMAS and FENECH, 2007), but exact role of aneuploidy in etiology of age-related 
neuronal degeneration is yet unclear (GRANIC et al., 2010; FAGGIOLI, 2011). One of the 
consequences of aneuploidy could be a predisposition to disease and in this respect aneuploidy 
has been implicated in the most common cause of dementia in AD. Aneuploidy is a feature of 
dividing cells, but it is present in neurons in both forms of AD (MOSCH et al., 2007), as well as in 
some peripheral cells of AD patients. The study of THOMAS and FENECH (2007) showed that 
SAD patients exhibit an abnormally high rate of chromosome 17 and 21 aneuploidy in buccal 
cells compared to controls. Buccal cells are of interest because they originate from ectoderm 
during embryogenesis, the germinal layer from which brain tissue and fibroblasts are derived 
(MIGLIORE, et al., 2011) and accordingly may exhibit genetic defects common to brain tissue. An 
increased aneuploidy was also detected in fibroblast culture from sporadic and familial AD 
patients (GELLER and POTTER, 1999); a significant approximately twofold increase was found in 
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the number of trisomy 21 cells compared to control cultures. Trisomy was not limited to 
chromosome 21 but extended at least to chromosome 18 as well. These data suggest that trisomy 
21 mosaicism may contribute to forms of AD that are not caused by presenilin mutation. 
 Premature centromere division (PCD) could be a manifestation of chromosome 
instability (MEHES and BUHLER, 1995) that leads to aneuploidy. Centromere is a chromosomal 
region, which holds sister chromatids between the end of replication and the start of segregation, 
playing a fundamental role in accurate chromosome segregation during mitosis and meiosis. 
PCD is connected with a loss of control over sequential separation and segregation of sister 
chromatids. Like aneuploidy, PCD has been correlating with both aging and AD in peripheral 
somatic cells (KORMANN-BORTOLOTTO et al., 1993; MIGLIORE et al., 1997; SPREMO-POTPAREVIC 
et al., 2004; ZIVKOVIC et al., 2010, 2013b). We have demonstrated, using the FISH technique, 
the PCD on X chromosome in the interphase neurons in the frontal cerebral cortex of female AD 
patients (SPREMO-POTPAREVIC et al., 2006, 2008; BAJIC et al., 2009). The presence of PCD on 
interphase chromosome is a proof that affected cells perform DNA replication and reenter into 
the cell cycle, because only replicated chromosomes can exhibit the phenomenon of PCD. Later 
on, a higher rate of PCD on chromosome X was found in lymphocytes from AD women in 
respect to healthy age-matched controls (ZIVKOVIC et al., 2006). KORMANN-BORTOLOTTO et al. 
(1993) were among the first to investigate peripheral blood lymphocytes from AD patients by 
cytogenetic probes. They found that aneuploidy, PCD and C-anaphase were not significantly 
different in AD patients comparing to age-matched controls, probably due to the small study 
population. In contrast, later results of other researchers consistently demonstrated an increased 
frequency of PCD in different chromosomes of AD lymphocytes, i.e., in acrocentrics (MIGLIORE 
et al., 1997; ZIVKOVIC et al., 2010) and chromosome 18 (ZIVKOVIC et al., 2006).  
Micronuclei (MNi) originate from acentric chromosome fragments or whole 
chromosomes that lag behind in anaphase and are left outside the daughter nuclei. Either they 
can originate from chromosome breakage or chromosome malsegregation events. Therefore, 
MNi are ideal biomarkers to investigate DNA damage at chromosomal levels (FENECH, 2000; 
DJELIC et al., 2006). MNi have been shown to be elevated in peripheral blood lymphocytes and 
skin fibroblasts in AD patients (MIGLIORE et al., 1999; PETROZZI et al., 2002; TRIPPI et al., 2011). 
Analysis of sensitivity of peripheral blood lymphocytes from AD patients to an aneuploidogenic 
drug griseofulvin, whose supposed target is microtubule-associated protein(s), showed that AD 
lymphocytes were characterized by lower levels of MN induction compare to controls (MIGLIORE 
et al., 1997), indicating that microtubule impairment might be associated with the disease. In the 
peripheral blood lymphocytes of AD patients, FISH data showed higher frequencies of 
chromosome 13 and 21 loss, evaluated as fluorescently labeled MNi, compared to control 
lymphocytes (MIGLIORE et al., 1999). More frequent chromosome 21 than chromosome 13 
malsegregation in somatic cells of AD subjects raised the hypothesis that mosaicism for 
chromosome 21 could underlie the dementia of AD phenotype (PETROZZI et al., 2002). Elevated 
MNi in AD lymphocytes were shown to be centromere positive, which indicates whole 
chromosome loss (TRIPPI et al., 2011).  In addition, the results of TRIPPI et al. (2011) confirmed 
that spontaneous frequency of MNi is increased in AD lymphocytes, but also showed that this 
phenomenon occurs in the skin fibroblasts of AD patients with either sporadic or familial form of 
disease. The authors supposed that different types of peripheral somatic cells of AD patients, 
irrespective of form of the disease, share similar feature leading to the occurrence at the same 
extent of cytogenetic anomalies. However, MNi frequency in buccal mucosa did not show a 
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significant difference between AD and control subjects (THOMAS et al., 2007), indicating that 
different types of peripheral AD cells do not necessarily express the same forms of chromosome 
instability. 
Telomere length may serve as an effective biomarker of a cell replicative history, aging 
and disease (ALLSOPP et al., 1992). Telomeres undergo shortening not only with each cell 
division, but also with aging and oxidative stress, all-important factors in AD. Moreover, 
telomere loss results in chromosomal instability (THOMAS and FENECH, 2007). Since SAD is 
highly related to age, examination of telomere length in AD neurons and peripheral cells seemed 
a promising technique to find the possible relationship between the telomere length and AD 
pathogenesis. However, conflicting results of hitherto investigations for the most part failed to 
establish such an association.    
Significantly shorter telomeres were found in hippocampal neurons in AD patients 
compared with that in control subjects, and they were not related to age either in control or AD 
subjects, as well as to amyloid deposits in AD patients (FRANCO et al., 2006). By contrast, 
THOMAS et al. (2008) reported that the mean telomere length in the brain hippocampal tissue was 
significantly longer in AD brains compared to normal brain tissue, which could be ascribed to a 
weaker proliferative capacity in cells within the dentate gyrus of the hippocampus, which 
continue to divide throughout adult life (ERIKSSON et al., 1998), or by telomere to telomere end 
fusions and amplification of telomere sequences due to breakage/fusion/bridge cycles (FENECH. 
and CROTT, 2002) after initial telomere shortening. 
Regarding the telomere length changing in peripheral cells from AD patients data are 
also inconclusive. In peripheral blood monocytes from AD subjects, significant telomere 
shortening was found in comparison to controls (PANOSSIAN et al., 2003). Telomere length of T 
lymphocytes, but not of B cells, has been correlated with AD status, suggesting possible immune 
alterations in AD pathogenesis. Similarly, telomere length in peripheral blood leukocytes and 
buccal cells from AD subjects were significantly shorter relative to corresponding values found 
in healthy age-matched controls (THOMAS et al., 2008). Recent work, in which telomere lengths 
were measured in leukocytes from patients with AD or mild cognitive impairment (MCI), 
displayed that patients with stable MCI that did not progress to AD had reduced telomere length 
compared to controls, whereas those with AD or MCI that later converted to AD have similar 
leukocyte telomere length as healthy controls (MOVERARE-SKRTIC et al., 2012). Furthermore, no 
correlations were found between leukocyte telomere lengths of AD patients arbitrary defined as 
highly positive for the core AD biomarkers, i.e., the cerebrospinal fluid levels of Aβ1-42, total 
tau and phosphorylated tau and the remaining patients or healthy controls. More recently, 
significantly shorter telomere length was found in peripheral blood monocytes in AD patients 
compared to controls, whereas telomeres of patients with MCI were not altered (HOCHSTRASSER 
et al., 2012). The discrepancy between these and results above  may be explained, at least partly, 
by the fact that first group (MOVERARE-SKRTIC et al., 2012) analyzed telomere length in the 
whole population of leukocytes, which is a mixture of different cell types. However, in another  
study, in which peripheral blood lymphocytes were investigated, no significant difference in 
telomere length was observed among large groups of cognitively normal subjects, demented 
patients (mixed dementia, AD and vascular dementia) and patients with MCI (ZEKRY et al.,  
2010). Similarly, no significant changes were found between patients with different etiologies or 
severity of dementia. These results suggest that telomere length could not be used to distinguish 
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between demented and non-demented subjects, regardless of type of dementia, or to predict 
dementia or mild cognitive impairment progression to dementia.  
Susceptibility to apoptosis and proliferative activity. Vast majority of experimental data 
demonstrate that peripheral cells in AD patients, primarily certain leukocyte subtypes, are more 
sensitive to spontaneous and induced apoptosis, and consequently more vulnerable than 
corresponding cells of age-matched control subjects. AD lymphocytes in culture exposed to 
DNA damaging chemical agents (bleomycin or methylmethane sulfonate) exhibit significantly 
enhanced DNA breakage rates for both drugs (CHERRY et al., 1992). The time course 
accumulation of apoptotic DNA fragments in lymphocytes from AD patients has also been 
reported in response to apoptotic stimuli (ECKERT et al., 1998). Lymphocytes of patients affected 
by SAD or FAD share an increased sensitivity to cell death, and enhanced vulnerability was 
most strongly developed in the CD4+ T-cell subtype (SCHINDOWSKI et al., 2003). The impact of 
SAD on CD4+ cell vulnerability was greater than that of FAD. Normal aging has also been 
shown to increase T cell susceptibility to apoptosis, but in contrast to AD it affected both CD4+ 
and CD8+ cells. Increased apoptosis was found in natural killer cells (SCHINDOWSKI et al., 2006) 
and in the peripheral blood monocytes from AD patients (BERGMAN et al., 2002) as well. 
Increased sensitivity of AD lymphocytes to apoptosis is accompanied by a decreased 
proliferative activity. Peripheral blood lymphocytes, stimulated with mitogen compounds, were 
less able to express CD69, an early proliferative marker, and expression level of CD69 of both 
T- and B-cells correlated inversely with the disease progress (STIELER et al., 2001). Proliferation 
activity of peripheral blood mononuclear cells to phytohemagglutinin has been shown to be 
significantly decreased in AD subjects (ZHANG et al., 2003), although Pannasonian et al. (2003) 
found that T-cells from AD patients respond more robustly to phytohemagglutinin than control 
cells.  
Possible causes of AD lymphocyte higher sensitivity to apoptosis are not clear. An 
investigation of the expression of some of apoptosis-related proteins (Bcl-2, Bax and caspase-3) 
in peripheral blood mononuclear cells from AD patients and healthy controls revealed no 
evidence of these proteins in AD cells (COSENTINO et al., 2009). On the other hand, a significant 
increase in the activity of caspase-3, -8 and -9, enzymes that play vital roles in the induction, 
transduction and amplification of intracellular apoptotic signals, was found in peripheral blood 
mononuclear cells of SAD patients relative to controls. This increased activity was not 
associated with increase in apoptosis, but was associated with a higher proliferative response to 
mitogens, suggesting that both altered caspase activation and altered proliferative response of 
peripheral blood mononuclear cells might reflect a general dysfunction of the cell cycle in AD 
(TACCONI et al., 2004). An extensive study of UBERTI and colleagues (2002) demonstrated a 
specific alteration of an intracellular pathway involved in sensing and repairing DNA damage in 
fibroblast from AD patients. AD fibroblast were shown to be less vulnerable to oxidative injury 
than non-AD cells and the protective mechanism was related to an impairment of H2O2-induced 
cell cycle arrest and characterized by an accelerated re-entry into the cell cycle and a diminished 
induction of apoptosis. Fibroblasts from AD patients also had a profound impairment in the 
H2O2-activated, p53-dependent pathway, which results in a lack of activation of p53 or p53-
target genes, including p21, GADD45 and bax. In addition, AD fibroblasts have been found to 
express a mutant-like p53 phenotype, which is virtually undetectable in fibroblasts of non-AD 
subjects (UBERTI et al., 2006). 
 
B. PLEČAŠ SOLAREVIĆ et al: PERIPHERAL CELLS IN ALZHEIMER'S DISEASE                                     323 
PUTATIVE CONSEQUENCES OF PERIPHERAL CELL  
GENOMIC/CHROMOSOME INSTABILITY 
 Functional consequences of the enhanced genome/chromosome instabilities in different 
types of peripheral somatic cells in AD patients, with the exception of blood mononuclear cells, 
at present are far from being understood. However, a prominent immune response, manifested as 
local inflammatory process has been shown to be associated with Aβ deposition and plaque 
formation in the central nervous system (BLASKO and GRUBECK-LOEBENSTEIN, 2003). Recent 
evidence suggest that inflammatory mechanisms represent, besides SPs and NFTs, a third 
component that may significantly contribute to AD progression and chronicity (HENEKA et al., 
2007). Abnormalities of both peripheral humoral and cellular immune responses in AD were 
reported, suggesting an association of immune deregulation and AD pathogenesis (LUGARESI et 
al., 2004; IARLORI et al., 2005). A variety of studies have shown that T lymphocytes isolated 
from peripheral blood of AD patients express alterations in distribution, proliferation, apoptosis 
and function, including expression of activation markers, disturbed calcium homeostasis and 
cytokine secretion (SCHINDOWSKI et al., 2007). T cells are activated and mainly display a 
memory phenotype (CD4). These T-cells are present both in the periphery and in the brain in AD 
patients (TOGO et al., 2002; TOWN et al., 2005), although they might play a role in AD without 
necessarily entering and/or taking up residence in the brain (PANOSSIAN et al., 2003). The exact 
roles of peripheral and T cells that entered the central nervous system in AD are still unclear. 
The presence of activated CD4+T cells might be the result of Aβ-specific chronic T cell 
stimulation, creating a pro-inflammatory environment, and enhancing disease progression 
(PELLICANO et al., 2012). The same authors conclude that there is a common peripheral immune 
profile for Alzheimer's disease which mainly involves CD4+ T cells, changes to which are 
consistent with chronic antigenic stress leading to immune exhaustion. Importantly, the changes 
in T lymphocyte phenotype and function could potentially affect vaccine-based efforts to 
modulate AD, and Aβ-reactive T-cell subsets seem to be major components of deleterious 
central nervous system response to active Aβ vaccination (GIUNTA et al., 2010). 
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Izvod 
Alchajmerova bolest (AB) je najučestaliji neurodegenerativni poremećaj starije populacije, 
praćen ireverzibilnim slabljenjem kognitivnih sposobnosti i demencijom. Kod 90% do 95% 
pacijenata bolest se javlja posle 65. godine života, kao sporadična forma (SAB). Uprkos 
istraživanjima koja traju više od jednog veka, etiologija i patogeneza, naročito SAB, nije 
objašnjena. Postoji nekoliko hipoteza o uzrocima neurodegeneracije kod AB; prema jednoj,  
glavni uzrok je genetska nestabilnost neurona određenih područja mozga i njihov ulazak u 
ponovni ćelijski ciklus, koji se posle određenog vremena rezultuje apoptozom. Iako AB 
prvenstveno oštećuje mozak, u literaturi su opisane brojne promene u perifernim tkivima 
ukazujući na to da je AB generalizovana sistemska bolest. One uključuju poremećaje ćeliskog 
ciklusa i hromozomsku nestabilnost, promene u proliferaciji i apoptozi, metabolizmu prekursora 
amiloidnog proteina i amiloidnog proteina β i brojnih drugih ćelijskih procesa. Ispitivanje lako 
dostupnih perifernih ćelija (ćelije krvi, fibroblasti kože, ćelije bukalne sluzokoža) ima značajnu 
ulogu u intenzivnoj potrazi za specifičnim i pouzdanim biomarkerima rane faze bolesti, tj., pre 
ispoljavanja kliničkih simptoma. U ovom radu ćemo sumirati naše i rezultate drugih autora koji 
se odnose na genetske, odnosno hromozomske poremećaje perifernih ćelija AB pacijenata i 
razmotrićemo njihovu moguću ulogu u patogenezi bolesti, kao i značaj daljih istraživanja u tom 
pravcu. 
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